Spero Therapeutics (SPRO) EPS (Basic) Growth (3y) (2019 - 2026)
Powered by 
Analysis
Spero Therapeutics (SPRO) EPS (Basic) Growth (3y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.70 Bn | 192.71 Bn | 7.24 Bn | 19.50% |
| 2 | Gilead Sciences | 180.18 Bn | 177.00 Bn | 6.22 Bn | -129.90% |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn | 6.85% |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | 11.71% |
| 5 | Argenx Se | 60.60 Bn | 55.42 Bn | 1.37 Bn | 86.03% |
| 6 | Moderna | 53.81 Bn | 48.67 Bn | 52.00 Mn | 18.44% |
| 7 | Alnylam Pharmaceuticals | 33.46 Bn | 30.15 Bn | 992.69 Mn | 36.73% |
| 8 | Biogen | 31.82 Bn | 30.54 Bn | 1.96 Bn | -45.60% |
| 9 | Roivant Sciences | 29.10 Bn | 29.10 Bn | 1.16 Mn | - |
| 10 | Spero Therapeutics | 66.37 Mn | 15.60 Mn | - | 10.07% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.07% |
| Mar 31, 2026 | 20.74% |
| Dec 31, 2025 | -9.14% |
| Sep 30, 2025 | 26.13% |
| Jun 30, 2025 | 66.20% |
| Mar 31, 2025 | 35.29% |
| Dec 31, 2024 | 24.91% |
| Sep 30, 2024 | 22.30% |
| Jun 30, 2024 | 18.96% |
| Mar 31, 2024 | 28.85% |
| Dec 31, 2023 | 46.74% |
| Sep 30, 2023 | 58.74% |
| Jun 30, 2023 | 36.66% |
| Mar 31, 2023 | 39.75% |
| Dec 31, 2022 | 35.83% |
| Sep 30, 2022 | 29.84% |
| Jun 30, 2022 | -1.55% |
| Mar 31, 2022 | -42.88% |
| Dec 31, 2021 | -10.25% |
| Sep 30, 2021 | -5.25% |